CRTX - Cortexyme: Valued On Skepticism
Company Overview
Cortexyme ([[CRTX]]) is a clinical-stage biopharmaceutical company pioneering a new disease-modifying therapeutic approach to treating Alzheimer’s disease and other neuro-degenerative diseases. The company is targeting a specific pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology. Cortexyme’s lead small molecule, COR388, has advanced through a Phase 1 trial and is currently the subject of a Phase 2/3 clinical trial in mild-to-moderate Alzheimer’s disease.
Investment Thesis
Cortexyme has been working to develop its lead Alzheimer's candidate, COR388. The drug is not based on the classical amyloid-beta hypothesis, making it